Peptide merchant accounts UK

Legal status (UK)

Sold lawfully in the UK only as research chemicals or laboratory reagents, labelled not for human consumption. Marketing peptides for human use, dosing or injection makes them unlicensed medicines and brings them under MHRA enforcement. The legal position turns entirely on how the product is presented.

Best way to take Peptide payments (UK)

High-risk merchants are the most exposed to chargebacks, frozen funds and MATCH/TMF listings, and that is exactly what your MerchantHQ account team handles, for the life of the agreement.

How Peptide placements work

Peptide routes to specialist regulated-vertical acquirers matched per application rather than a published list. The right underwriter depends on your licence, volume and sub-category, so we approach it individually. We hold the relationships and disclose your risk classification upfront so the right acquirer is contacted from the start.

Typical pricing

Rate

3.5% to 8.0% blended

Settlement reserve

10% to 20% rolling reserve common

Indicative ranges based on typical UK high-risk acquirer pricing for this category. Your actual rate and reserve are set per merchant at underwriting and will differ.

Watch outs

• Product pages must label peptides as research chemicals not for human consumption; any human-use, dosing or injection guidance reclassifies them as unlicensed medicines under MHRA rules and triggers acquirer termination.
• No medical, therapeutic, performance or anti-ageing claims anywhere on site, in metadata or in ads.
• Mainstream processors (Stripe, PayPal, SumUp) routinely freeze peptide accounts post-onboarding once the category is identified; have a compliant specialist account in place from day one.
• Age-gating, COA / batch documentation and clear returns terms are reviewed at underwriting.
• GLP-1 peptides (semaglutide, tirzepatide) are prescription-only medicines, not research chemicals; selling them without a pharmacy registration is a separate and more serious offence.
• A certificate of analysis or lab test is required for every product, not a sample of the range; peptide catalogues are typically coded MCC 5999.
• Peptides sold in pill or capsule form are widely treated as intended for human consumption and are refused outright by many acquirers under internal policy; keep the catalogue to non-oral formats.
• Most underwriters require a fixed in-vitro disclaimer in every product description: used solely for in vitro experiments, not for use in human clinical trials, human administration, or supply to a third party for human investigational use.
• If semaglutide is listed, expect to provide a letter confirming compliance with the requirements to sell it, or to remove the products before an acquirer will proceed.